Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 5
Submit an article Journal homepage
1,329
Views
7
CrossRef citations to date
0
Altmetric
Research Paper

Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine

Chiemi HottaDepartment of Molecular Virology, Graduate School of Medicine, Chiba University, Chuo-ku, Japan;Division of Virology and Medical zoology, Chiba Prefectural Institute of Public Health, Chuo-ku, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4228-6628
ORCID Icon,
Tomoko OgawaDivision of Virology and Medical zoology, Chiba Prefectural Institute of Public Health, Chuo-ku, Japan
&
Hiroshi ShirasawaDepartment of Molecular Virology, Graduate School of Medicine, Chiba University, Chuo-ku, JapanORCID Iconhttps://orcid.org/0000-0001-5213-7242
ORCID Icon
Pages 1154-1159 | Received 01 Oct 2018, Accepted 14 Jan 2019, Published online: 11 Mar 2019

References

  • World Health Organization. Global eradication of poliomyelitis by the year 2000. Forty first World Health Assembly, resolution 41.28. WHO, Geneva, Switzerland, 1988.
  • Polio Grobal Eradication Initiative. Polio eradication & endgame strategic plan 2013–2018. WHO, Geneva, Switzerland, 2013.
  • WHO. Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec. 2016;91(12):145–68. PMID:27039410.
  • Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210 Suppl 1:S380–9. doi:10.1093/infdis/jiu184. PubMed PMID: 25316859.
  • Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine. 1996;14(8):735–46. PubMed PMID: 8817819.
  • Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from sabin strains (DTaP-sIPV). J Infect Dis. 2013;208(2):275–83. Epub 2013/ 04/08. doi:10.1093/infdis/jit155. PubMed PMID: 23568174.
  • Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237–43. Epub 2011/ 12/08. doi:10.1093/infdis/jir723. PubMed PMID: 22158682.
  • Resik S, Tejeda A, Fonseca M, Alemañi N, Diaz M, Martinez Y, Garcia G, Okayasu H, Burton A, Bakker WA, et al. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba. Vaccine. 2014;32(42):5399–404. Epub 2014/ 08/12. doi:10.1016/j.vaccine.2014.07.109. PubMed PMID: 25131734.
  • Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW. Development of inactivated poliovirus vaccine from Sabin strains: A progress report. Biologicals. 2016;44(6):581–87. Epub 2016/ 10/05. doi:10.1016/j.biologicals.2016.08.005. PubMed PMID: 27720268.
  • Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34(16):1975–85. Epub 2014/ 11/21. doi:10.1016/j.vaccine.2014.11.015. PubMed PMID: 25448090.
  • National Institute of Infectious Diseases. Poliomyelitis, Japan, 1962–1995. IASR. 1997;18(1):28–29.
  • Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65. Epub 2010/05/12. doi:10.1128/CVI.00131-10. PubMed PMID: 20463105; PubMed Central PMCID: PMCPMC2897268.34.
  • Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine. 2011;29(46):8205–14. Epub 2011/ 09/05. doi:10.1016/j.vaccine.2011.08.059. PubMed PMID: 21896299.
  • Maldonado YA, Peña-Cruz V, de la Luz Sanchez M, Logan L, Blandón S, Cantwell MF, Matsui SM, Millan-Velasco F, Valdespino JL, Sepulveda J. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis. 1997;175(3):545–53. doi:10.1093/infdis/175.3.545. PubMed PMID: 9041324.
  • Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV). Hum Vaccin. 2010;6(7):554–61. doi:10.4161/hv.6.7.11760. PubMed PMID: 20448468.
  • Centers for Disease Control and Prevention (U.S.). Poliomyelitis. In: Hamborsky J, Kroger A, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Washington (DC) Public Health Foundation, 2015. p. 297–310.
  • Böttiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine. 1990;8(5):443–45. doi:10.1016/0264-410X(90)90244-G. PubMed PMID: 2251870.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.